In this interview, Jon Haulenbeek (Bristol-Myers Squibb; NJ, USA) discusses his role as a Group Leader running the Reagent Center of Excellence in the Translational Medicine Division. He explains that the role of his group is procuring, characterizing and storing critical reagents for regulated PK and immunogenicity assays. Key questions that are explored include:
- How Bristol-Myers Squibb use LBA for characterization?
- What are the current best practices for critical reagent characterization?
- How Bristol-Myers Squibb use HRMS for biophysical characterization?
- Where he hopes the field will be in 5–10 years’ time?